These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23548958)

  • 41. Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy.
    Prabhu N; Kapur N; Catalona W; Leikin R; Helenowski I; Jovanovich B; Gurley M; Okwuosa TM; Kuzel TM
    Urol Oncol; 2021 Feb; 39(2):130.e9-130.e15. PubMed ID: 33132024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
    Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
    Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncologic outcomes after minimally invasive radical prostatectomy in patients with seminal vesicle invasion (pT3b) without adjuvant therapy.
    Forgues A; Rozet F; Audenet F; Ouzzane A; Sanchez-Salas R; Barret E; Galiano M; Prapotnich D; Cathelineau X
    World J Urol; 2014 Apr; 32(2):519-24. PubMed ID: 23881352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy.
    Huynh LM; Keit E; Schuller AA; Carrillo RC; Huang E; Ahlering TE; Boyle S; Enke C; Baine MJ
    World J Urol; 2021 Sep; 39(9):3287-3293. PubMed ID: 33502557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients.
    Ku JH; Jeong CW; Park YH; Cho MC; Kwak C; Kim HH
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):63-8. PubMed ID: 20938462
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
    Ho T; Gerber L; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):910-6. PubMed ID: 22921964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined reporting of cancer control and functional results of radical prostatectomy.
    Salomon L; Saint F; Anastasiadis AG; Sebe P; Chopin D; Abbou CC
    Eur Urol; 2003 Dec; 44(6):656-60. PubMed ID: 14644116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Salvage radical prostatectomy for recurrent prostate cancer. Morbidity, oncological and functional results].
    Vidmar R; Marcq G; Flamand V; Fantoni JC; Hénon F; Villers A; Ouzzane A
    Prog Urol; 2017; 27(8-9):458-466. PubMed ID: 28576424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.
    Rantaniemi L; Tammela TLJ; Kujala P; Murtola TJ
    Scand J Urol; 2018 Aug; 52(4):269-276. PubMed ID: 30362865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
    Jeong BC; Chalfin HJ; Lee SB; Feng Z; Epstein JI; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
    Eur Urol; 2015 Feb; 67(2):342-6. PubMed ID: 24968968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
    Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
    Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.